HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.
Key Details
- 1FDA grants 510(k) clearance to HeartLung Corporation's AI-CVD algorithm.
- 2AI-CVD performs 11 opportunistic screening assessments on chest CT scans.
- 3Assesses for findings like coronary calcium, valve and wall calcium, volumetry, lung and liver attenuation, bone mineral density, and more.
- 4Alerts doctors to incidental findings that may indicate risk for conditions such as heart disease, stroke, osteoporosis, diabetes, and liver steatosis.
- 5Can be used for both new and prior CT scans, supporting broader preventive care.
- 6Platform potentially applicable to nearly 40 million CT scans per year in the U.S.
Why It Matters
This clearance introduces the most comprehensive FDA-cleared AI platform for opportunistic screening on CT, enabling earlier identification of at-risk patients and broadening the utility of routine imaging for preventive care. Radiology practices may see an expanded role in population health management through automated, multi-disease detection.
Source
Cardiovascular Business
Related News
•AuntMinnie
GPT-4o AI Matches Radiologists in Follow-Up Imaging Recommendations
GPT-4o matched the performance of experienced radiologists and surpassed residents in recommending follow-up imaging from routine radiology reports.
•Cardiovascular Business
AI Leverages Head CTs for Automated Heart Risk Assessments
AI models can turn routine head CT scans into automated cardiovascular risk assessments, expanding the utility of radiology studies.
•Radiology Business
MRI AI for Parkinsonian Syndrome Gains FDA De Novo Clearance
Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.